NDATRANSDERMALSYSTEM
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
ADLARITY (donepezil hydrochloride) by PharmaIN is 12. Approved for alzheimer's disease. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADLARITY (donepezil hydrochloride) is a reversible acetylcholinesterase inhibitor approved for Alzheimer's disease and cognitive dysfunction. It works by increasing acetylcholine concentration in the brain to enhance cholinergic neurotransmission and improve cognitive function. The product is available as a transdermal system, a novel formulation of the established donepezil mechanism.
$2MPart D
Peak12.3 years to LOEEarly-stage peak lifecycle product with modest Part D uptake; limited commercial team expansion expected given small initial volume.
Mechanism of Action
12.1 Mechanism of Action Current theories on the pathogenesis of the cognitive signs and symptoms of Alzheimer's disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function.…
Worked on ADLARITY at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.